By Michael Dabaie

Merck & Co. Inc. said the European Commission granted marketing authorization for Verquvo to Bayer AG.

In the EU, Verquvo is indicated for the treatment of symptomatic chronic heart failure. Verquvo is being jointly developed by Merck and Bayer. Merck has the commercial rights in the U.S. and Bayer has the exclusive commercial rights in the rest of world.

The U.S. Food and Drug Administration in January approved Verquvo to reduce the risk of cardiovascular death and heart failure hospitalization.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

July 21, 2021 08:10 ET (12:10 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Bayer.
Bayer (TG:BAYN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Bayer.